Antengene Corporation Limited
Antengene Corporation Limited (6996) is a biotechnology company focused on the discovery, development, and commercialization of innovative therapies for cancer treatment. The company operates primarily in the biopharmaceutical sector, concentrating on the development of monoclonal antibodies, small molecules, and other biologics aimed at addressing unmet medical needs in oncology. Antengene's core products include a pipeline of drug candidates designed to target various cancers, with efforts in both domestic and international markets.